{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:46:03Z","timestamp":1787222763057,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Aerie Pharmaceuticals Limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s12325-021-01634-9","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T22:02:48Z","timestamp":1614204168000},"page":"1757-1775","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Phase\u00a02 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension"],"prefix":"10.1007","volume":"38","author":[{"given":"Makoto","family":"Araie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Aso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kanemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyani","family":"Kothapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Kopczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Senchyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"key":"1634_CR1","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311:1901\u201311.","journal-title":"JAMA"},{"key":"1634_CR2","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081\u201390.","journal-title":"Ophthalmology"},{"key":"1634_CR3","unstructured":"Japan Glaucoma Society Glaucoma Practice Guidelines Development Committee. Glaucoma medical care guideline 4th edition. Nichigankaishi. 2018;122:5\u201353."},{"key":"1634_CR4","first-page":"1641","volume":"111","author":"A Iwase","year":"2004","unstructured":"Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi study. Ophthalmology. 2004;111:1641\u20138.","journal-title":"Ophthalmology"},{"key":"1634_CR5","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.ophtha.2005.05.012","volume":"112","author":"T Yamamoto","year":"2005","unstructured":"Yamamoto T, Iwase A, Araie M, et al. Prevalence of primary angle closure and secondary glaucoma in a Japanese population. Ophthalmology. 2005;112:1661\u20139.","journal-title":"Ophthalmology"},{"key":"1634_CR6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/archophthalmol.2008.593","volume":"127","author":"M Pekmezci","year":"2009","unstructured":"Pekmezci M, Vo B, Lim AK, et al. The characteristics of glaucoma in Japanese Americans. Arch Ophthalmol. 2009;127:167\u201371.","journal-title":"Arch Ophthalmol"},{"key":"1634_CR7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","volume":"130","author":"The AGIS Investigators","year":"2000","unstructured":"The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429\u201340.","journal-title":"Am J Ophthalmol"},{"key":"1634_CR8","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(04)16257-0","volume":"363","author":"RN Weinreb","year":"2004","unstructured":"Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363:1711\u201320.","journal-title":"Lancet"},{"key":"1634_CR9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/ICU.0b013e32834ff23e","volume":"23","author":"WD Stamer","year":"2012","unstructured":"Stamer WD, Acott TS. Current understanding of conventional outflow dysfunction in glaucoma. Curr Opin Ophthalmol. 2012;23:135\u201343.","journal-title":"Curr Opin Ophthalmol"},{"key":"1634_CR10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00055735-200404000-00011","volume":"15","author":"K Schwartz","year":"2004","unstructured":"Schwartz K, Budenz D. Current management of glaucoma. Curr Opin Ophthalmol. 2004;15:119\u201326.","journal-title":"Curr Opin Ophthalmol"},{"key":"1634_CR11","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268\u201379.","journal-title":"Arch Ophthalmol"},{"key":"1634_CR12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701\u201313 (Discussion 829\u201330).","journal-title":"Arch Ophthalmol"},{"key":"1634_CR13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/archophthalmol.2010.20","volume":"128","author":"MA Kass","year":"2010","unstructured":"Kass MA, Gordon MO, Gao F, et al. Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol. 2010;128:276\u201387.","journal-title":"Arch Ophthalmol"},{"key":"1634_CR14","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0002-9394(98)00272-4","volume":"126","author":"Collaborative Normal-Tension Glaucoma Study Group","year":"1998","unstructured":"Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498\u2013505.","journal-title":"Am J Ophthalmol"},{"key":"1634_CR15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coph.2012.09.012","volume":"13","author":"C Bucolo","year":"2013","unstructured":"Bucolo C, Salomone S, Drago F, Reibaldi M, Longo A, Uva MG. Pharmacological management of ocular hypertension: current approaches and future prospective. Curr Opin Pharmacol. 2013;13:50\u20135.","journal-title":"Curr Opin Pharmacol"},{"key":"1634_CR16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/2040622313511286","volume":"5","author":"D Sambhara","year":"2014","unstructured":"Sambhara D, Aref AA. Glaucoma management: relative value and place in therapy of available drug treatments. Ther Adv Chronic Dis. 2014;5:30\u201343.","journal-title":"Ther Adv Chronic Dis"},{"key":"1634_CR17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2147\/OPTH.S15971","volume":"5","author":"J Chen","year":"2011","unstructured":"Chen J, Runyan SA, Robinson MR. Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011;5:667\u201377.","journal-title":"Clin Ophthalmol"},{"key":"1634_CR18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/jop.2013.0197","volume":"30","author":"CC Kopczynski","year":"2014","unstructured":"Kopczynski CC, Epstein DL. Emerging trabecular outflow drugs. J Ocul Pharmacol Ther. 2014;30:85\u20137.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1634_CR19","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1167\/iovs.05-1617","volume":"48","author":"H Tokushige","year":"2007","unstructured":"Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of Y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2007;48:3216\u201322.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1634_CR20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/IJG.0b013e3182952213","volume":"24","author":"RF Wang","year":"2015","unstructured":"Wang RF, Williamson JE, Kopczynski C, Serle JB. Effect of 0.04% AR-13324, a ROCK and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015;24:51\u20134.","journal-title":"J Glaucoma"},{"key":"1634_CR21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.exer.2016.08.023","volume":"158","author":"PV Rao","year":"2017","unstructured":"Rao PV, Pattabiraman PP, Kopczynski C. Role of the Rho GTPase\/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: bench to bedside research. Exp Eye Res. 2017;158:23\u201332.","journal-title":"Exp Eye Res"},{"key":"1634_CR22","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/aos.12829","volume":"94","author":"H Tanihara","year":"2016","unstructured":"Tanihara H, Inoue T, Yamamoto T, et al. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94:e26\u201334.","journal-title":"Acta Ophthalmol"},{"key":"1634_CR23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IJG.0000000000001203","volume":"28","author":"H Saito","year":"2019","unstructured":"Saito H, Kagami S, Mishima K, Mataki N, Fukushima A, Araie M. Long-term side effects including blepharitis leading to discontinuation of ripasudil. J Glaucoma. 2019;28:289\u201393.","journal-title":"J Glaucoma"},{"key":"1634_CR24","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.ophtha.2009.06.024","volume":"116","author":"JC Tsai","year":"2009","unstructured":"Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009;116:S30\u20136.","journal-title":"Ophthalmology"},{"key":"1634_CR25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejphar.2016.04.002","volume":"787","author":"G Li","year":"2016","unstructured":"Li G, Mukherjee D, Navarro I, et al. Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes. Eur J Pharmacol. 2016;787:20\u201331.","journal-title":"Eur J Pharmacol"},{"key":"1634_CR26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1089\/jop.2017.0023","volume":"34","author":"CW Lin","year":"2018","unstructured":"Lin CW, Sherman B, Moore LA, et al. Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma. J Ocul Pharmacol Ther. 2018;34:40\u201351.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1634_CR27","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1167\/iovs.16-20189","volume":"57","author":"R Ren","year":"2016","unstructured":"Ren R, Li G, Le TD, Kopczynski C, Stamer WD, Gong H. Netarsudil increases outflow facility in human eyes through multiple mechanisms. Invest Ophthalmol Vis Sci. 2016;57:6197\u2013209.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1634_CR28","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1089\/jop.2017.0138","volume":"34","author":"A Kazemi","year":"2018","unstructured":"Kazemi A, McLaren JW, Kopczynski CC, Heah TG, Novack GD, Sit AJ. The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans. J Ocul Pharmacol Ther. 2018;34:380\u20136.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1634_CR29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/jop.2014.0146","volume":"31","author":"JW Kiel","year":"2015","unstructured":"Kiel JW, Kopczynski C. Effect of AR-13324 on episcleral venous pressure in Dutch Belted rabbits. J Ocul Pharmacol Ther. 2015;31:146\u201351.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1634_CR30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-018-0877-7","volume":"78","author":"SM Hoy","year":"2018","unstructured":"Hoy SM. Netarsudil ophthalmic solution 0.02%: first global approval. Drugs. 2018;78:389\u201396.","journal-title":"Drugs"},{"key":"1634_CR31","first-page":"2460","volume":"58","author":"JH Peace","year":"2017","unstructured":"Peace JH, Kopczynski C, Heah TGH. Ocular hypotensive efficacy of netarsudil ophthalmic solution 002% over a 24-hour period: a pilot study. Investig Ophthalmol Vis Sci. 2017;58:2460.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1634_CR32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2019.01.003","volume":"200","author":"MY Kahook","year":"2019","unstructured":"Kahook MY, Serle JB, Mah FS, et al. Long-term safety and ocular hypotensive efficacy evaluation of netarsudil ophthalmic solution: rho kinase elevated IOP treatment trial (ROCKET-2). Am J Ophthalmol. 2019;200:130\u20137.","journal-title":"Am J Ophthalmol"},{"key":"1634_CR33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ajo.2019.03.002","volume":"204","author":"AS Khouri","year":"2019","unstructured":"Khouri AS, Serle JB, Bacharach J, et al. Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study. Am J Ophthalmol. 2019;204:97\u2013104.","journal-title":"Am J Ophthalmol"},{"key":"1634_CR34","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","volume":"186","author":"JB Serle","year":"2018","unstructured":"Serle JB, Katz LJ, McLaurin E, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure. Am J Ophthalmol. 2018;186:116\u201327.","journal-title":"Am J Ophthalmol"},{"key":"1634_CR35","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ophtha.2014.08.022","volume":"122","author":"J Bacharach","year":"2015","unstructured":"Bacharach J, Dubiner HB, Levy B, Kopczynski CC, Novack GD, AR-13324-CS202 Study Group. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology. 2015;122:302\u20137.","journal-title":"Ophthalmology"},{"key":"1634_CR36","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/archopht.124.9.1230","volume":"124","author":"MB Sherwood","year":"2006","unstructured":"Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006;124:1230\u20138.","journal-title":"Arch Ophthalmol"},{"key":"1634_CR37","first-page":"679","volume":"29","author":"M Araie","year":"2012","unstructured":"Araie M, Yamazaki Y, Sugiyama K, Kuwayama Y, Tanihara H. Long-term safety and efficacy of brimonidine ophthalmic solution in patients with primary open angle glaucoma or ocular hypertension. Atarashii Ganka (J Eye). 2012;29:679\u201386.","journal-title":"Atarashii Ganka (J Eye)"},{"key":"1634_CR38","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","volume":"156","author":"H Tanihara","year":"2013","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M, K-115 Clinical Study Group. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156:731\u20136.","journal-title":"Am J Ophthalmol"},{"key":"1634_CR39","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10384-011-0048-9","volume":"55","author":"H Watabe","year":"2011","unstructured":"Watabe H, Abe S, Yoshitomi T. Effects of Rho-associated protein kinase inhibitors Y-27632 and Y-39983 on isolated rabbit ciliary arteries. Jpn J Ophthalmol. 2011;55:411\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"1634_CR40","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/IJG.0000000000001634","volume":"29","author":"IP Singh","year":"2020","unstructured":"Singh IP, Fechtner RD, Myers JS, et al. Pooled efficacy and safety profile of netarsudil ophthalmic solution 0.02% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2020;29:878\u201384.","journal-title":"J Glaucoma"},{"key":"1634_CR41","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0002-9394(02)01980-3","volume":"135","author":"WC Stewart","year":"2003","unstructured":"Stewart WC, Kolker AE, Stewart JA, Leech J, Jackson AL. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol. 2003;135:314\u201320.","journal-title":"Am J Ophthalmol"},{"key":"1634_CR42","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0039-6257(97)00118-5","volume":"42","author":"M Mantyjarvi","year":"1998","unstructured":"Mantyjarvi M, Tuppurainen K, Ik\u00e4heimo K. Ocular side effects of amiodarone. Surv Ophthalmol. 1998;42:360\u20136.","journal-title":"Surv Ophthalmol"},{"key":"1634_CR43","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/01.icu.0000143688.45232.15","volume":"15","author":"DA Hollander","year":"2004","unstructured":"Hollander DA, Aldave AJ. Drug-induced corneal complications. Curr Opin Ophthalmol. 2004;15:541\u20138.","journal-title":"Curr Opin Ophthalmol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01634-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-021-01634-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01634-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T19:07:40Z","timestamp":1616872060000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-021-01634-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,24]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1634"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01634-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,24]]},"assertion":[{"value":"23 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}